kabutan

TOWA PHARMACEUTICAL CO.,LTD., July-September (2Q) Ordinary Profit Decreases by 47%

Tue Nov 12, 2024 3:30 pm JST Earnings

4553 TOWA PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

TOWA PHARMACEUTICAL CO.,LTD. <4553> [TSE-P] announced its financial results after the market closed on November 12th (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2025 (April to September) was 10.3 billion yen, a 1.0% increase compared to the same period last year. However, The progress rate against the 22.7 billion yen full-year plan was 45.5%, also falling below the five-year average of 56.5%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to decrease by 13.2% from the same period last year to 12.3 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated ordinary profit dropped to 1.74 billion yen, a 46.7% decrease compared to the same period last year. However, the operating profit margin improved from 5.5% in the same period last year to 8.0%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2022 90,500 3,220 4,609 2,692 54.7 89.7 Nov 14, 2022 J-GAAP
Apr - Sep, 2023 107,396 7,003 10,233 6,953 141.3 41.8 Nov 13, 2023 J-GAAP
Apr - Sep, 2024 123,404 10,513 10,338 6,555 133.2 45.5 Nov 12, 2024 J-GAAP
YoY +14.9% +50.1% +1.0% -5.7% -5.7%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 Guidance 123,400 10,500 10,300 6,500 132.0 30 Nov 5, 2024 J-GAAP
Apr - Sep, 2024 Results 123,404 10,513 10,338 6,555 133.2 30 Nov 12, 2024 J-GAAP
Revision Rate +0.0% +0.1% +0.4% +0.8% +0.9%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2023 120,538 10,644 14,244 9,220 187.3 30 May 14, 2024 J-GAAP
Oct - Mar, 2024 Guidance 138,696 12,787 12,362 8,445 171.6 30 Nov 12, 2024 J-GAAP
YoY +15.1% +20.1% -13.2% -8.4% -8.4%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 208,859 5,514 5,141 2,201 44.7 60 May 15, 2023 J-GAAP
Mar, 2024 227,934 17,647 24,477 16,173 328.6 60 May 14, 2024 J-GAAP
Mar, 2025 Guidance 262,100 23,300 22,700 15,000 304.7 60 Nov 5, 2024 J-GAAP
YoY +15.0% +32.0% -7.3% -7.3% -7.3%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2023 52,848 2,907 3,274 2,203 44.8 5.5 Nov 13, 2023 J-GAAP
Oct - Dec, 2023 60,929 6,201 6,936 4,565 92.8 10.2 Feb 13, 2024 J-GAAP
Jan - Mar, 2024 59,609 4,443 7,308 4,655 94.6 7.5 May 14, 2024 J-GAAP
Apr - Jun, 2024 62,566 5,672 8,593 5,495 111.6 9.1 Aug 8, 2024 J-GAAP
Jul - Sep, 2024 60,838 4,841 1,745 1,060 21.5 8.0 Nov 12, 2024 J-GAAP
YoY +15.1% +66.5% -46.7% -51.9% -51.9%

Related Articles